Skip to main content
SpringerLink
Log in

Endocrine Therapy of Breast Cancer

  • Chapter
Book cover Breast Cancer in Women of African Descent

  • 443 Accesses

Abstract

Breast cancer is one of the most common cancers in the Western world. Although the incidence of breast cancer in white women is higher than in black women, mortality from breast cancer is relatively higher in African- Americans. This has been shown in several large cancer surveillance studies (1–2). The survival disadvantage of African-American women is due to numerous factors, the most important of which is stage of disease at the time of diagnosis. It has been shown in multiple studies, that black women are more likely to present with more advanced disease (3–4), including more patients with inoperable breast cancer and with nodal involvement. The differences in breast cancer stage and biology at presentation between Caucasian and African-American patients are reviewed extensively in Chapters 2 and 3.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Axtell LM, Myers MH: Contrasts in survival of black and white cancer patients, 1960–73. J Natl Cancer Inst 1978;60:1209–15.

    CAS  PubMed  Google Scholar 

  2. Young JL, Jr., Ries LG, Pollack ES: Cancer patient survival among ethnic groups in the United States. J Natl Cancer Inst 1984;73:341–52.

    PubMed  Google Scholar 

  3. Natarajan N, Nemoto T, Mettlin C, Murphy GP: Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons. Cancer 1985;56:1704–9.

    Article  CAS  PubMed  Google Scholar 

  4. Eley JW, Hill HA, Chen VW, Austin DF, Wesley MN, Muss HB, et al: Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. Jama 1994;272:947–54.

    Article  CAS  PubMed  Google Scholar 

  5. McWhorter WP, Mayer WJ: Black/white differences in type of initial breast cancer treatment and implications for survival. Am J Public Health 1987;77:1515–7.

    Article  CAS  PubMed  Google Scholar 

  6. Yood MU, Johnson CC, Blount A, Abrams J, Wolman E, McCarthy BD, et al: Race and differences in breast cancer survival in a managed care population. J Natl Cancer Inst 1999;91:1487–91.

    Article  CAS  PubMed  Google Scholar 

  7. Heimann R, Ferguson D, Powers C, Suri D, Weichselbaum RR, Hellman S: Race and clinical outcome in breast cancer in a series with long-term follow-up evaluation. J Clin Oncol 1997;15:2329–37.

    CAS  PubMed  Google Scholar 

  8. Mohla S, Sampson CC, Khan T, Enterline JP, Leffall L, Jr., White JE: Estrogen and progesterone receptors in breast cancer in Black Americans:Correlation of receptor data with tumor differentiation. Cancer 1982;50:552–9.

    Article  CAS  PubMed  Google Scholar 

  9. Beverly LN, Flanders WD, Go RC, Soong SJ: A comparison of estrogen and progesterone receptors in black and white breast cancer patients. Am J Public Health 1987;77:351–3.

    Article  CAS  PubMed  Google Scholar 

  10. Beatson G: On the treatment of inoperable cases of the mamma:suggestions for a new method of treatment with illustrative cases. Lancet 1896;2:104–07.

    Article  Google Scholar 

  11. Schinzinger A: Centralblatt fur Chirurgie. Beilage 1889;18:55–56.

    Google Scholar 

  12. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;351:1451–67.

    Google Scholar 

  13. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1992;339:1–15.

    Google Scholar 

  14. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1992;339:71–85.

    Google Scholar 

  15. Eifel P, Axelson JA, Costa J, Crowley J, Curran WJ, Jr., Deshler A, et al: National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1–3, 2000. J Natl Cancer Inst 2001;93:979–89.

    Article  CAS  PubMed  Google Scholar 

  16. Thurlimann B:Breast Cancer. International Consensus Meeting of the Treatment of Primary Breast Cancer. Switzerland: St. Gallen, 2001, p. 294–97.

    Google Scholar 

  17. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, et al: Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 1996;88:1529–42.

    Article  CAS  PubMed  Google Scholar 

  18. Morrow M, Jordan VC: Molecular mechanisms of resistance to tamoxifen therapy in breast cancer. Arch Surg 1993;128:1187–91.

    CAS  PubMed  Google Scholar 

  19. Gottardis MM, Jordan VC: Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res 1988;48:5183–7.

    CAS  PubMed  Google Scholar 

  20. Masamura S, Santner SJ, Heitjan DF, Santen RJ: Estrogen deprivation causes estradiol hypersensitivity in human breast cancer cells. J Clin Endocrinol Metab 1995;80:2918–25.

    Article  CAS  PubMed  Google Scholar 

  21. Cuzick J, Powles T, Veronesi U, Forbes J, Edwards R, Ashley S, et al: Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003;361:296–300.

    Article  CAS  PubMed  Google Scholar 

  22. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, et al: Tamoxifen for prevention of breast cancer:report of the National Surgical Adjuvant Breast and Bowel Project P-l Study. J Natl Cancer Inst 1998;90:1371–88.

    Article  CAS  PubMed  Google Scholar 

  23. McDonald CC, Stewart HJ: Fatal myocardial infarction in the Scottish adjuvant tamoxifen trial. The Scottish Breast Cancer Committee. Bmj 1991;303:435–7.

    Article  CAS  PubMed  Google Scholar 

  24. Costantino JP, Kuller LH, Ives DG, Fisher B, Dignam J: Coronary heart disease mortality and adjuvant tamoxifen therapy. J Natl Cancer Inst 1997;89:776–82.

    Article  CAS  PubMed  Google Scholar 

  25. Rutqvist LE, Mattsson A: Cardiac and thromboembolic morbidity among postmenopausal women with early-stage breast cancer in a randomized trial of adjuvant tamoxifen. The Stockholm Breast Cancer Study Group. J Natl Cancer Inst 1993;85:1398–406.

    Article  CAS  PubMed  Google Scholar 

  26. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women’s Health Initiative randomized controlled trial. Jama 2002;288:321–33.

    Article  CAS  PubMed  Google Scholar 

  27. Love RR, Mazess RB, Tormey DC, Barden HS, Newcomb PA, Jordan VC: Bone mineral density in women with breast cancer treated with adjuvant tamoxifen for at least two years. Breast Cancer Res Treat 1988;12:297–302.

    Article  CAS  PubMed  Google Scholar 

  28. Love RR, Mazess RB, Barden HS, Epstein S, Newcomb PA, Jordan VC, et al: Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 1992;326:852–6.

    Article  CAS  PubMed  Google Scholar 

  29. Fallowfield L CD: Assessing the quality of life (QOL) of postmenopausal (PM) women radomized into the ATAC (‘Arimidex’ tamoxifen, alone or in combination) adjuvant breast cancer (BC) trial. Proc. Am. Soc. Clin. Oncol 2002;21.

    Google Scholar 

  30. Bonneterre J, Thurlimann B, Robertson JF, Krzakowski M, Mauriac L, Koralewski P, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women:results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748–57.

    CAS  PubMed  Google Scholar 

  31. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, et al: Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women:results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758–67.

    CAS  PubMed  Google Scholar 

  32. Bonneterre J, Buzdar A, Nabholtz JM, Robertson JF, Thurlimann B, von Euler M, et al: Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:2247–58.

    Article  CAS  PubMed  Google Scholar 

  33. Mouridsen H, Gershanovich M, Sun Y, Perez-Carrion R, Boni C, Monnier A, et al: Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001;19:2596–606.

    CAS  PubMed  Google Scholar 

  34. Paridaens R, Dirix L, Beex L, Nooij MN, Cufer T, Lohrisch C, et al: Promising Results with Exemestane in the First-Line Treatment of Metastatic Breast Cancer: A Randomized Phase II EORTC Trial with a Tamoxifen Control. Clin Breast Cancer 2000;1 Suppl 1:S19–21.

    Article  Google Scholar 

  35. Rose C, Vtoraya O, Pluzanska A, Neave F, Clemens M, Chaudri-Ross HA, et al: Letrozole (Femara) vs. anastrozole (Arimidex). Proc. Am. Soc. Clin. Oncol 2002;21.

    Google Scholar 

  36. Crump M, Sawka CA, DeBoer G, Buchanan RB, Ingle JN, Forbes J, et al: An individual patient-based meta-analysis of tamoxifen versus ovarian ablation as first line endocrine therapy for premenopausal women with metastatic breast cancer. Breast Cancer Res Treat 1997;44:201–10.

    Article  CAS  PubMed  Google Scholar 

  37. Taylor CW, Green S, Dalton WS, Martino S, Rector D, Ingle JN, et al: Multicenter randomized clinical trial of goserelin versus surgical ovariectomy in premenopausal patients with receptor-positive metastatic breast cancer:an intergroup study. J Clin Oncol 1998;16:994–9.

    CAS  PubMed  Google Scholar 

  38. Klijn JG, Blarney RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R: Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer:a meta-analysis of four randomized trials. J Clin Oncol 2001;19:343–53.

    CAS  PubMed  Google Scholar 

  39. Boccardo F, Rubagotti A, Perrotta A, Amoroso D, Balestrero M, De Matteis A, et al: Ovarian ablation versus goserelin with or without tamoxifen in pre-perimenopausal patients with advanced breast cancer: results of a multicentric Italian study. Ann Oncol 1994;5:337–42.

    CAS  PubMed  Google Scholar 

  40. Lonning PE, Taylor PD, Anker G, Iddon J, Wie L, Jorgensen LM, et al: High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Res Treat 2001;67:111–6.

    Article  CAS  PubMed  Google Scholar 

  41. Peethambaram PP, Ingle JN, Suman VJ, Hartmann LC, Loprinzi CL: Randomized trial of diethylstilbestrol vs. tamoxifen in postmenopausal women with metastatic breast cancer. An updated analysis. Breast Cancer Res Treat 1999;54:117–22.

    Article  CAS  Google Scholar 

  42. Cauley JA, Norton L, Lippman ME, Eckert S, Krueger KA, Purdie DW, et al: Continued breast cancer risk reduction in postmenopausal women treated with raloxifene:4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 2001;65:125–34.

    Article  CAS  PubMed  Google Scholar 

  43. Jordan VC, Glusman JE, Eckert S: Raloxifene reduces incident primary breast cancer. Breast Cancer Res Treat 1998;50:227.

    Google Scholar 

  44. Buzdar AU, Marcus C, Holmes F, Hug V, Hortobagyi G: Phase II evaluation of Lyl56758 in metastatic breast cancer. Oncology 1988;45:344–5.

    Article  CAS  PubMed  Google Scholar 

  45. Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, et al: Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386–95.

    Article  CAS  PubMed  Google Scholar 

  46. Howell A, Robertson JF, Quaresma Albano J, Aschermannova A, Mauriac L, Kleeberg UR, et al: Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396–403.

    Article  CAS  PubMed  Google Scholar 

  47. Ovarian ablation in early breast cancer: overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1996;348:1189–96.

    Google Scholar 

  48. Davidson NE: Ovarian ablation as adjuvant therapy for breast cancer. J Natl Cancer Inst Monogr 2001;30:67–71.

    PubMed  Google Scholar 

  49. Dees EC, Davidson NE: Ovarian ablation as adjuvant therapy for breast cancer. Semin Oncol 2001;28:322–31.

    Article  CAS  PubMed  Google Scholar 

  50. Jonat W, Kaufmann M, Sauerbrei W, Blarney R, Cuzick J, Namer M, et al: Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study. J Clin Oncol 2002;20:4628–35.

    Article  CAS  PubMed  Google Scholar 

  51. Cuzick J: The ATAC (‘Arimidex’, Tamoxifen, Alone or in Combination) trial in postmenopuasal women with early breast cancer — updated efficacy results based on a median follow-up of 47 months. The Breast 2003;12:47.

    Article  Google Scholar 

  52. Baum M: The ATAC (Arimidex, Tamoxifen, Alone or in Combination) adjuvant breast cancer trial in postmenopausal patients: factors influencing the success of patient recruitment. Eur J Cancer 2002;38:1984–6.

    Article  CAS  PubMed  Google Scholar 

  53. Winer EP, Hudis C, Burstein HJ, Chlebowski RT, Ingle JN, Edge SB, et al: American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol 2002;20:3317–27.

    Article  CAS  PubMed  Google Scholar 

  54. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003;349:1793–1802.

    Article  CAS  PubMed  Google Scholar 

  55. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 2001;19:881–94.

    CAS  PubMed  Google Scholar 

  56. Dewar J, Nabholtz JM, Bonneterre J, Buzdar A, Robertson JF, Thurlimann B, et al: The effect of anastrozole (Arimidex) on serum lipids — data from a randomized comparison of anastrozole (AN) vs. tamoxifen (TAM) in postmenopausal (PM) women with advanced breast cancer (ABC). Breast Cancer Res Treat 2000;64.

    Google Scholar 

  57. Harper-Wynne C, Ross G, Sacks N, Salter J, Nasiri N, Iqbal J, et al: Effects of the aromatase inhibitor letrozole on normal breast epithelial cell proliferation and metabolic indices in postmenopausal women: a pilot study for breast cancer prevention. Cancer Epidemiol Biomarkers Prev 2002;11:614–21.

    CAS  PubMed  Google Scholar 

  58. Elisaf MS, Bairaktari ET, Nicolaides C, Kakaidi B, Tzallas CS, Katsaraki A, et al: Effect of letrozole on the lipid profile in postmenopausal women with breast cancer. Eur J Cancer 2001;37:1510–3.

    Article  CAS  PubMed  Google Scholar 

  59. Goss PE, Grynpas M, Qui S, Hu H: The effects of exemestane on bone and lipids in the ovariectomized rat. Breast Cancer Res Treat 2001;69.

    Google Scholar 

  60. Goss PE, Cheung AM, Lowery C: Comparison of the efffects of exemestane, 17-hydroexemestane and letrozole on bone and lipid metabolism inthe ovariectomized rat. Breast Cancer Res Treat 2002;76.

    Google Scholar 

  61. Goss PE, Thomsen T, Banke-Bochita J: A randomized, placebo-controlled, explorative study to investigate the effect of low estrogen plasma levels on markers of bone turnover in healthy postmenopausal women during the 12 week treatment with exemestane or letrozole. Breast Cancer Res Treat 2002;76.

    Google Scholar 

  62. Lohrisch C, Paridaens R, Dirix L, Beex L, Nooij MN, Cameron D, et al: No adverse impact on serum lipids of the irreversible aromatase inactivator Aromasin (exemestan [ED]) in 1st line treatment of metastatic breast cancer (MBC) : companion study to a European Organization of Research and Treatment of Breast Cancer (Breast Group) trial with Pharmacias’ Upjohn. Proc. Am. Soc. Clin. Oncol 2001;20.

    Google Scholar 

  63. Dirix L, Piccart M, Lohrisch C, Beex L, Nooij MN, Biganzoli L, et al: Efficacy of and tolerance to exemestane (E) versus tamoxifen (T) in fist line hormone therapy (HT) of postmenopausal metastatic breast cancer (MBC) patients (pts): A European Organisation for the Research and Treatment of Cancer (EORTC Breast Group) phase II trial with Pharmacia and Upjohn,. Proc. Am. Soc. Clin. Oncol 2001;20.

    Google Scholar 

  64. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;352:930–42.

    Google Scholar 

  65. Albain K, Green S, Ravdin P, Cobau C, Levine EG, Ingle JN: Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100(SWOG-8814). Proc. Am. Soc. Clin. Oncol 2002;21.

    Google Scholar 

  66. Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 1989;7:710–7.

    CAS  PubMed  Google Scholar 

  67. Castiglione-Gertsch M, Oneill A, Gelber RD, Nasi ML: Is the addition of adjuvant chemotherapy always necessary in node negative (N-) pre/perimenopausal breast cancer patients (pts) who receive goserelin? First results of IBCSG trial VIII. Proc. Am. Soc. Clin. Oncol 2002;21.

    Google Scholar 

  68. Nicholson RI, McClelland RA, Robertson JF, Gee JM: Involvement of steroid hormone and growth factor cross-talk in endocrine response in breast cancer. Endocr Relat Cancer 1999;6:373–87.

    Article  CAS  PubMed  Google Scholar 

  69. Johnston SR, Head J, Pancholi S, Detre S, Martin LA, Smith IE, et al: Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003;9:524S–32S.

    CAS  PubMed  Google Scholar 

  70. Bunone G, Briand PA, Miksicek RJ, Picard D: Activation of the unliganded estrogen receptor by EGF involves the MAP kinase pathway and direct phosphorylation. Embo J 1996;15:2174–83.

    CAS  PubMed  Google Scholar 

  71. Simoncini T, Hafezi-Moghadam A, Brazil DP, Ley K, Chin WW, Liao JK: Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase. Nature 2000;407:538–41.

    Article  CAS  PubMed  Google Scholar 

  72. Webb P, Lopez GN, Uht RM, Kushner PJ: Tamoxifen activation of the estrogen receptor/AP-1 pathway: potential origin for the cell-specific estrogen-like effects of antiestrogens. Mol Endocrinol 1995;9:443–56.

    Article  CAS  PubMed  Google Scholar 

  73. Wright C, Nicholson S, Angus B, Sainsbury JR, Farndon J, Cairns J, et al: Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer 1992;65:118–21.

    CAS  PubMed  Google Scholar 

  74. Massarweh S, Shou J, DiPietro M, Mohsin SK, Hilsenbeck SG: Targeting the epidermal growth factor receptor pathway improves the ant-tumor effect of tamoxifen and delays acquired resistance in xenograft model of breast Cancer. Breast Cancer Res Treat 2002;33.

    Google Scholar 

  75. Johnston SR: Farnesyl transferase inhibitors: a novel targeted tnerapy for cancer. Lancet Oncol 2001;2:18–26.

    Article  CAS  PubMed  Google Scholar 

  76. Kelland LR, Smith V, Valenti M, Patterson L, Clarke PA, Detre S, et al: Preclinical antitumor activity and pharmacodynamic studies with the farnesyl protein transferase inhibitor R1 15777 in human breast cancer. Clin Cancer Res 2001;7:3544–50.

    CAS  PubMed  Google Scholar 

  77. Johnston SR, Hickish T, Houston S, Ellis PA: Efficacy and tolerability of two dosing regimens of R1 15777 (Zarnestra), a farnesyl protein transferase inhibitor, in patients with advanced breast cancer. Proc. Am. Soc. Clin. Oncol 2002;21.

    Google Scholar 

  78. Chan A, Johnston SR, Scheulen ME, Mross K: First report: a phase 2 study of the safety and activity of CCI-779 for patients with locally advanced or metastatic breast cancer failing prior chemotherapy. Proc. Am. Soc. Clin. Oncol 2002;21.

    Google Scholar 

  79. Pesenti E, Masferrer JL, Di Salle E: Effect if exenestane and celecoxib alone or in combingation on DMBA-induced mammary carcinoma in rats. Breast Cancer Res Treat 2003;69.

    Google Scholar 

  80. Dignam JJ: Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin 2000;50:50–64.

    Article  CAS  PubMed  Google Scholar 

  81. Christian MC, Trimble EL: Increasing participation of physicians and patients from underrepresented racial and ethnic groups in National Cancer Institute-sponsored Clinical Trials. Cancer Epidemiol Biomarkers Prev 2003;12:277S–83S.

    PubMed  Google Scholar 

  82. Tejeda HA, Green SB, Trimble EL, Ford L, High JL, Ungerleider RS, et al: Representation of African-Americans, Hispanics, and whites in National Cancer Institute cancer treatment trials. J Natl Cancer Inst 1996;88:812–6.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. First Medical Department with Medical Oncology, Wilhelminen Hospital, Montleartstr. 37, A-1160, Vienna, Austria

    Kathrin Strasser-Weippl MD

  2. Department of Medical Oncology and Hematology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada

    Paul E. Goss MD, FRCPC, FRCP (UK), PhD

  3. Harvard Medical School, Boston, MA, USA

    Paul E. Goss MD, FRCPC, FRCP (UK), PhD

Authors
  1. Kathrin Strasser-Weippl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paul E. Goss MD, FRCPC, FRCP (UK), PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. British Columbia Cancer Agency, Nanaimo, Canada

    Christopher Kwesi O. Williams (Senior Editor) (Senior Editor)

  2. University of British Columbia, Vancouver, Canada

    Christopher Kwesi O. Williams (Senior Editor) (Senior Editor)

  3. University of Chicago, Chicago, IL, USA

    Olufunmilayo I. Olopade (Editor) (Editor)

  4. University of Alabama at Birmingham Comprehensive Cancer Center, Birmingham, AL, USA

    Carla I. Falkson (Editor) (Editor)

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer

About this chapter

Cite this chapter

Strasser-Weippl, K., Goss, P.E. (2006). Endocrine Therapy of Breast Cancer. In: Williams, C.K.O., Olopade, O.I., Falkson, C.I. (eds) Breast Cancer in Women of African Descent. Springer, Dordrecht. https://doi.org/10.1007/978-1-4020-3664-4_9

Download citation

Publish with us

Policies and ethics

Search

Navigation